What are the side effects of Trastuzumab injection (subcutaneous injection) (Herceptin Hylecta)?

Trastuzumab injection (subcutaneous ) (Herceptin Hylecta) is a fixed-dose combination drug used to treat HER2-overexpressing adult breast cancer. It is a combination of trastuzumab and hyaluronidase. In clinical studies, the most common adverse reactions of any grade (occurring in ≥10% of patients) were alopecia, nausea, ARRs, neutropenia, diarrhea, asthenia, fatigue, vomiting, myalgia, decreased appetite, stomatitis, arthralgia, headache, rash, constipation, radiation skin damage, pyrexia, cough, and anemia.

Trastuzumab injection (subcutaneous injection) After being put on the market, adverse events such as glomerular disease, tumor lysis syndrome (TLS), oligohydramnios or oligohydramnios sequence, including pulmonary hypoplasia, skeletal abnormalities and neonatal death, have occurred. Warnings and precautions such as cardiomyopathy, embryo-fetal toxicity, pulmonary toxicity, exacerbation of neutropenia caused by chemotherapy, allergies and administration-related reactions have also appeared. Use of trastuzumab injection (subcutaneous injection) during pregnancy can cause embryo-fetal damage. It is therefore recommended that women of childbearing potential use effective contraception during treatment and for 7 months after the last dose.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Since the drug has been on the market for a short time, it has not been included in the scope of medical insurance. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.